The effectiveness of PARP inhibitors for biliary tract cancer remains unclear, as fewer patients with BRCA1/2 germline mutations present with biliary tract cancer compared to those presenting with pancreatic cancer. This evidence concerns the gene BRCA1 and biliary tract cancer.